[18F]DCFPyL PET/CT imaging in prostate cancer patients: a prospective study on safety, lesion detection rate, and impact on management

Conclusions: [18F]DCFPyL is a safe and sensitive radiopharmaceutical for the detection of prostate cancer. It also improved decision making for referring physicians and changed management for the majority of participants.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Rousseau, E., Wilson, D., Lacroix-Poisson, F., Krauze, A., Chi, K., Gleave, M., McKenzie, M., Tyldesley, S., Goldenberg, S. L., Benard, F. Tags: Prostate Diagnosis II Source Type: research